Since September 2008, Thomas Boehm has been part of the Clinical Development team at Intercell AG, a Vienna based biotechnology company focussing on vaccine development for infectious diseases.

During medical school, he finished a thesis in the laboratory of Helmut Sinzinger before joining the laboratory of Bernd Binder. After medical school, he spent 8 years as a postdoctoral fellow, first working on the yeast cell cycle with Kim Nasmyth at the Institute of Molecular Pathology (IMP) in Vienna (now Trinity College), University of Oxford, and then studying anti-angiogenesis as a new treatment for cancer with the late Judah Folkman at Children's Hospital, Harvard Medical School in Boston. In 2000, Boehm completed the full-time MBA program at INSEAD, Fontainebleau, before joining the Boston office of TVM, a Munich-based life science Venture Capital investment firm analysing many biotechnology start-up companies working on new treatments in a variety of different medical indications. In August 2004 he joined Jerini AG in Berlin and worked until June 2007 as Medical Director in the Clinical Development team. In August 2007 he joined Bavarian Nordic in Munich to work on clinical development programs for several new vaccines. 

Thomas holds an M.D. from the Medical School of Vienna.

• How Can We Explain the American Dominance in Biomedical Research and Development? (September 20, 2005)